期刊文献+

热消融技术治疗甲状腺微小乳头状癌的研究进展

Research progress of thermal ablation in the treatment of thyroid micropapillary carcinoma
下载PDF
导出
摘要 甲状腺癌是最常见的头颈部恶性肿瘤,其中以甲状腺乳头状癌最常见,直径≤1.0 cm的甲状腺乳头状癌称为甲状腺微小乳头状癌。近年来热消融技术治疗甲状腺微小乳头状癌在国内外迅速发展,有较好的临床疗效和安全性。目前国内外发布了较多与甲状腺微小乳头状癌热消融治疗相关的指南、共识和临床研究,但关于热消融治疗甲状腺微小乳头状癌的适应证在不同指南中存在差异,其中低危微小甲状腺乳头状癌是目前多数指南推荐的甲状腺热消融技术的适应证,但低危微小甲状腺乳头状癌的定义仍有争议。本文基于现有文献、指南、临床研究,总结甲状腺癌热消融治疗的优势、适应证、疗效、安全性、消融后的中医药治疗以及存在的问题,并进行概述、探讨和分析。 Thyroid cancer is the most common malignant tumor of the head and neck,among which papillary thyroid carcinoma is the most common.Papillary thyroid carcinoma with a diameter of≤1.0 cm is called thyroid micropapillary carcinoma.In recent years,thermal ablation technology for the treatment of thyroid micropapillary carcinoma has developed rapidly at home and abroad.At present,many guidelines,consensus and clinical studies related to thermal ablation treatment of thyroid micropapillary carcinoma have been published at home and abroad.Based on the existing literature,guidelines and clinical studies,this article summarizes,discusses and analyzes the advantages,indications,efficacy,safety,and existing problems of thermal ablation therapy for thyroid cancer.
作者 刘津 王小平 瞿琳娣 王群 高瑛 顾渊 贡翊斐 李涛 唐晓丹 石坤和 LIU Jin;WANG Xiaoping;QU Lindi;WANG Qun;GAO Ying;GU Yuan;GONG Yifei;LI Tao;TANG Xiaodan;SHI Kunhe(DepartmentⅢof Surgery,Shanghai municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200071,China)
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2024年第6期1041-1046,共6页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 国家中医药管理局科研项目(No.2018ZY03005) 上海市科学技术委员会项目(No.17401933) 上海市中医医院“未来计划”项目(No.WLJH2021ZYMZY009)。
关键词 甲状腺微小乳头状癌 热消融技术 临床研究 micropapillary carcinoma of the thyroid gland thermal ablation technology clinical research
  • 相关文献

参考文献20

二级参考文献308

  • 1范建霞,关海霞,吕朝晖,田文,武晓泓,无.妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识(2019版)[J].中国实用外科杂志,2020,40(3):255-259. 被引量:12
  • 2田志平,张冰,张丹,张晓朦,林志健.基于Meta分析的小金丸治疗甲状腺结节疗效与安全性评价[J].药物流行病学杂志,2020,29(2):84-88. 被引量:11
  • 3商洪才,王保和,张伯礼.中药新药证候及疗效评价[J].中药新药与临床药理,2004,15(5):365-368. 被引量:219
  • 4Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States,1973-2002[J].JAMA,2006,295(18):2164-2167.
  • 5Mazzaferri EL,Jhiang SM.Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J].Am J Med,1994,97(5):418-428.
  • 6Xing M.BRAF mutation in thyroid cancer[J].Endocr Relat Cancer,2005,12(2):245-262.
  • 7Liu D,Liu Z,Condouris S,et al.BRAF V6OOE maintains proliferation,transformation,and tumorigenicity of BRAF-mutant papillary thyroid cancer cells[J].J Clin Endoerinol Metab,2007,92(6):2264-2271.
  • 8Tang KT,Lee CH.BRAF mutation in papillary thyroid carcinoma:pathogenic role and clinical implications[J].J Chin Med Assoc,2010,73(3):113-128.
  • 9O'Neill CJ,Bullock M,Chou A,et al.BRAF(V600E)mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer[J].Surgery,2010,148(6):1139-1145.
  • 10Salvatore G,De Falco V,Salerno P,et al.BRAF is a therapeutic target in aggressive thyroid carcinoma[J]J Clin Cancer Res,2006,12(5):1623-1629.

共引文献844

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部